- Home
- ARVN vs EBS Comparison
ARVN vs EBS Comparison
Compare ARVN & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- EBS
- Stock Information
- Founded
- ARVN 2015
- EBS 1998
- Country
- ARVN United States
- EBS United States
- Employees
- ARVN N/A
- EBS N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- ARVN Health Care
- EBS Health Care
- Exchange
- ARVN Nasdaq
- EBS Nasdaq
- Market Cap
- ARVN 456.2M
- EBS 393.9M
- IPO Year
- ARVN 2018
- EBS 2006
- Fundamental
- Price
- ARVN $7.53
- EBS $6.64
- Analyst Decision
- ARVN Buy
- EBS Strong Buy
- Analyst Count
- ARVN 21
- EBS 3
- Target Price
- ARVN $20.53
- EBS $14.33
- AVG Volume (30 Days)
- ARVN 2.2M
- EBS 1.2M
- Earning Date
- ARVN 07-29-2025
- EBS 05-07-2025
- Dividend Yield
- ARVN N/A
- EBS N/A
- EPS Growth
- ARVN N/A
- EBS N/A
- EPS
- ARVN N/A
- EBS N/A
- Revenue
- ARVN $426,900,000.00
- EBS $965,400,000.00
- Revenue This Year
- ARVN $2.83
- EBS N/A
- Revenue Next Year
- ARVN N/A
- EBS $18.88
- P/E Ratio
- ARVN N/A
- EBS N/A
- Revenue Growth
- ARVN 498.74
- EBS N/A
- 52 Week Low
- ARVN $5.90
- EBS $4.02
- 52 Week High
- ARVN $34.11
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- ARVN 54.38
- EBS 58.90
- Support Level
- ARVN $6.70
- EBS $6.01
- Resistance Level
- ARVN $7.60
- EBS $6.62
- Average True Range (ATR)
- ARVN 0.45
- EBS 0.37
- MACD
- ARVN 0.15
- EBS -0.03
- Stochastic Oscillator
- ARVN 95.04
- EBS 61.88
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.